Literature DB >> 18056176

A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.

Karsten Gravdal1, Ole J Halvorsen, Svein A Haukaas, Lars A Akslen.   

Abstract

PURPOSE: Cell adhesion molecules are of crucial importance in cancer invasion and metastasis. Epithelial to mesenchymal transition, characterized by reduced E-cadherin and increased N-cadherin expression, has been recognized as a feature of aggressive tumors, but the importance of this phenotype has not been settled in human prostate cancer. We here present novel data, with special focus on the independent relationship between an E-cadherin to N-cadherin switch (EN-switch) and patient prognosis. EXPERIMENTAL
DESIGN: Tissue microarray sections from a consecutive series of 104 radical prostatectomies during 1988 to 1994 with detailed clinicopathologic data and long follow-up were studied immunohistochemically for the expression of E-cadherin, N-cadherin, P-cadherin, beta-catenin, and p120(CTN).
RESULTS: Low E-cadherin expression was significantly associated with adverse clinicopathologic features, whereas other biomarkers were mostly related to Gleason score. In univariate survival analyses, cadherin switching (high N-cadherin and low E-cadherin) showed strong and significant associations with multiple end points of progression and cancer-specific death. Expression of the "basal cell marker" P-cadherin was associated with shorter time to skeletal metastasis (P = 0.036). In multivariate analysis of time to clinical recurrence, the "EN-switch" (hazard ratio, 4.3; P < 0.0005) had strong and independent prognostic effect, together with Gleason score.
CONCLUSION: These novel data unravel the importance of epithelial to mesenchymal transition for prostate cancer progression, and demonstration of a switch from E-cadherin to N-cadherin expression could have significant effect on the care of prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056176     DOI: 10.1158/1078-0432.CCR-07-1263

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  203 in total

1.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms.

Authors:  Y-N Liu; J J Yin; W Abou-Kheir; P G Hynes; O M Casey; L Fang; M Yi; R M Stephens; V Seng; H Sheppard-Tillman; P Martin; K Kelly
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

Review 2.  Isolated, disseminated and circulating tumour cells in prostate cancer.

Authors:  David Schilling; Tilman Todenhöfer; Jörg Hennenlotter; Christian Schwentner; Tanja Fehm; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

3.  Cooperative involvement of NFAT and SnoN mediates transforming growth factor-β (TGF-β) induced EMT in metastatic breast cancer (MDA-MB 231) cells.

Authors:  Suman Sengupta; Samir Jana; Subir Biswas; Palash Kumar Mandal; Arindam Bhattacharyya
Journal:  Clin Exp Metastasis       Date:  2013-07-06       Impact factor: 5.150

Review 4.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming.

Authors:  Xiaopeng Liu; Hao Sun; Jing Qi; Linli Wang; Songwei He; Jing Liu; Chengqian Feng; Chunlan Chen; Wen Li; Yunqian Guo; Dajiang Qin; Guangjin Pan; Jiekai Chen; Duanqing Pei; Hui Zheng
Journal:  Nat Cell Biol       Date:  2013-05-26       Impact factor: 28.824

6.  Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.

Authors:  Malik Quasir Mahmood; Chris Ward; Hans Konrad Muller; Sukhwinder Singh Sohal; Eugene Haydn Walters
Journal:  Med Oncol       Date:  2017-02-14       Impact factor: 3.064

7.  Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Authors:  Andressa Ardiani; Sofia R Gameiro; Claudia Palena; Duane H Hamilton; Anna Kwilas; Thomas H King; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

8.  Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.

Authors:  Tanya Stoyanova; Mireille Riedinger; Shu Lin; Claire M Faltermeier; Bryan A Smith; Kelvin X Zhang; Catherine C Going; Andrew S Goldstein; John K Lee; Justin M Drake; Meghan A Rice; En-Chi Hsu; Behdokht Nowroozizadeh; Brandon Castor; Sandra Y Orellana; Steven M Blum; Donghui Cheng; Kenneth J Pienta; Robert E Reiter; Sharon J Pitteri; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-30       Impact factor: 11.205

9.  Holding Tight: Cell Junctions and Cancer Spread.

Authors:  Alexander J Knights; Alister P W Funnell; Merlin Crossley; Richard C M Pearson
Journal:  Trends Cancer Res       Date:  2012

10.  Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.

Authors:  Eoin P Brennan; Karen A Nolan; Emma Börgeson; Oisín S Gough; Caitríona M McEvoy; Neil G Docherty; Debra F Higgins; Madeline Murphy; Denise M Sadlier; Syed Tasadaque Ali-Shah; Patrick J Guiry; David A Savage; Alexander P Maxwell; Finian Martin; Catherine Godson
Journal:  J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.